New York, NY -- (SBWIRE) -- 01/23/2014 -- PennyStockChronicle covers the breadth of the markets, from NASDAQ, NYSE, AMEX, ETF, Penny Stocks, Emerging Markets, activities at the Fed and more. PennyStockChronicle brings you the most vibrant coverage of following stocks: Earthlink Holdings Corp (NASDAQ:ELNK), Lloyds Banking Group PLC (ADR) (NYSE:LYG), CytRx Corporation (NASDAQ:CYTR), Newcastle Investment Corp (NYSE:NCT)
Earthlink Holdings Corp (NASDAQ:ELNK) showed a volume of 1.43 million shares by the end of last trade whereas the average volume of the stock remained 1.12 million shares. The stock opened the session at $4.76 but then moved to $4.70. At that price, the stock showed a negative performance of -0.63%. EarthLink Holdings Corp, formerly EarthLink, Inc., is a network, communications and information technology (IT) services provider to business and residential customers in the United States.
Will ELNK Get Buyers Even After The Recent Rally? Find Out Here
Lloyds Banking Group PLC (ADR) (NYSE:LYG) opened the session at $5.61 and closed the session at $5.62. Traded with volume of 1.43 million shares in the prior session and the average volume of the stock remained 3.22 million shares. Lloyds Banking Group plc is a holding company. The Company is a financial services group providing a range of banking and financial services, primarily in the United Kingdom, to personal and corporate customers. It operates in four segments: Retail,
Is LYG a Solid Investment at These Levels? Read This Report For Details
CytRx Corporation (NASDAQ:CYTR) opened the session at $7.43 and closed the session at $7.22. The stock showed a negative performance of -1.63% in previous trading session. Traded with volume of 1.42 million shares in the prior session and the average volume of the stock remained 6.31 million shares. The beta of the stock remained 1.33. CytRx Corporation (CytRx) is a biopharmaceutical research and development company specializing in oncology. The Company's oncology pipeline includes three programs in clinical development for cancer indications: INNO-206, tamibarotene and bafetinib.
Why Should Investors Buy CYTR After the Recent Fall? Just Go Here and Find Out
Newcastle Investment Corp (NYSE:NCT) the stock advanced 0.68% and finished the session at $5.90. Traded with volume of 1.41 million shares in the prior session and the average volume of the stock remained 3.72 million shares. The beta of the stock remained 3.23. Newcastle Investment Corp. (Newcastle) is a real estate investment and finance company. Newcastle invests in, and actively manages, a portfolio of, real estate securities, loans, excess mortgage servicing rights (MSRs) and other real estate related assets.
Will NCT Continue To Move Higher? Find Out Here
Penny Stock Chronicle is comprised of a team of vetted penny stock traders who’ve been trading since 2008 & have developed the skills needed to trade for consistent profits.
PLEASE NOTE WELL: The employees of PennyStockChronicle.com are not registered as Investment Advisors in any jurisdiction whatsoever. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Investing in “penny stocks” is highly speculative.
Verify all claims and do your own due diligence on all securities. PennyStockChronicle.com profiles are not a solicitation or recommendation to buy, sell or hold securities. PennyStockChronicle.com is not offering securities for sale. Neither PennyStockChronicle.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor under any federal or state law and none of the information provided by PennyStockChronicle.com, its owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or investment recommendations. PennyStockChronicle.com does not recommend that the securities profiled should be purchased, sold or held.
Read Full Disclaimer at: http://pennystockchronicle.com/disclaimer
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)